Deploying regulated AI is no small feat, as highlighted by Erez Kaminski, CEO of Ketryx and former AI strategist for Amgen. With the FDA’s recent rollout of its internal AI tool, Elsa, the complexities of regulatory compliance are becoming increasingly apparent. Kaminski emphasizes that the challenges go beyond just the sheer volume of regulatory documents; they also involve the architecture of AI systems themselves. He advocates for a hybrid approach that combines the strengths of large language models with the structured logic of symbolic AI, enabling a more efficient and effective review process.